Latest Breaking News On - Artiva allo - Page 2 : comparemela.com

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesFrankfurt am mainBaden wübergWolfgang fischerArtiva alloMary beth sandinAlexander fudukidisIoanna tsoukalaEuropean hematology associationUniversity of texas md anderson cancer centerInstitute for tumor biologyAnnounces acceptancePreclinical dataInnate cell engagerHind medyoufTumor biology

Affimed N V : Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

Affimed N V : Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergAlexander fudukidisHye ryun kimArtiva alloDennis riedlMary beth sandinAmerican society of clinical oncologyUniversity of texas md anderson cancer centerClinical oncologyHye ryunPresentation timeCancer centerAktien sie

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been.

United statesBaden wübergMary beth sandinHye ryun kimAlexander fudukidisArtiva alloAmerican society of clinical oncologyUniversity of texas md anderson cancer centerGlobenewswire incClinical oncologyDevelopmental therapeuticsPresentation timeCancer center

Affimed Reports 2023 Financial Results and Operational

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer.

United statesBaden wübergAndreas harstrickArtiva alloAlexander fudukidisUniversity of texas md anderson cancer centerInternational accounting standard boardProgram updatesInternational financial reporting standardsSafety review committeeExchange commissionChief medical officerChief executive officerAccepted accountingCancer centerNasdaq afmd

Innate cell engagers for lymphoma treatment

Innate cell engagers for lymphoma treatment
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Merck seronoEli lillyAndreas harstrickArtiva alloSciences at imclone systems incMd anderson cancer centerArtiva incHannover medical schoolDrug administrationUniversity of essenGlobal clinical development unitChief medical officerPeripheralt cellFast trackMolecular partnersSenior vice president